DK0416855T3 - Fede syrer til behandling og undgåelse af hudbeskadigelser forårsager af radioterapi - Google Patents

Fede syrer til behandling og undgåelse af hudbeskadigelser forårsager af radioterapi

Info

Publication number
DK0416855T3
DK0416855T3 DK90309638.6T DK90309638T DK0416855T3 DK 0416855 T3 DK0416855 T3 DK 0416855T3 DK 90309638 T DK90309638 T DK 90309638T DK 0416855 T3 DK0416855 T3 DK 0416855T3
Authority
DK
Denmark
Prior art keywords
treating
skin damage
radiotherapy
fatty acids
damage caused
Prior art date
Application number
DK90309638.6T
Other languages
English (en)
Inventor
David Frederick Horrobin
Catherine Ann Scott
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10662681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0416855(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of DK0416855T3 publication Critical patent/DK0416855T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Amplifiers (AREA)
  • Bipolar Transistors (AREA)
DK90309638.6T 1989-09-07 1990-09-04 Fede syrer til behandling og undgåelse af hudbeskadigelser forårsager af radioterapi DK0416855T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898920228A GB8920228D0 (en) 1989-09-07 1989-09-07 Fatty acid therapy

Publications (1)

Publication Number Publication Date
DK0416855T3 true DK0416855T3 (da) 1994-02-14

Family

ID=10662681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90309638.6T DK0416855T3 (da) 1989-09-07 1990-09-04 Fede syrer til behandling og undgåelse af hudbeskadigelser forårsager af radioterapi

Country Status (14)

Country Link
EP (1) EP0416855B1 (da)
JP (1) JPH0399013A (da)
KR (1) KR910005858A (da)
AT (1) ATE98121T1 (da)
AU (1) AU633618B2 (da)
CA (1) CA2024724A1 (da)
DE (1) DE69005062T2 (da)
DK (1) DK0416855T3 (da)
FI (1) FI904403A0 (da)
GB (1) GB8920228D0 (da)
HK (1) HK74694A (da)
IE (1) IE63449B1 (da)
NZ (1) NZ235203A (da)
ZA (1) ZA907040B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5690947A (en) * 1996-08-30 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids
GB9621373D0 (en) * 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
HUP0001938A3 (en) * 1997-01-24 2001-09-28 Univ California Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation
US5855893A (en) * 1997-02-14 1999-01-05 Elizabeth Arden Co., Division Of Conopco, Inc. Trichodesma lanicum seed extract as an anti-irritant in compositions containing hydroxy acids or retinoids
FR2765482B1 (fr) * 1997-07-07 2000-12-08 Oreal Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
GB9724802D0 (en) * 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
CA2599112C (en) 2005-02-14 2013-10-22 Suntory Limited Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR102391827B1 (ko) 2014-06-04 2022-04-27 디에스 바이오파마 리미티드 Dgla를 포함하는 약제학적 조성물 및 그의 용도
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2024163448A1 (en) * 2023-01-30 2024-08-08 Cold Spring Harbor Laboratory Use of arachidonic acid for amelioration of cytotoxic effects from chemotherapy and radiation therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205076A (en) * 1982-08-09 1985-04-30 Univ California Protecting and healing gastro-duodenal mucosa and the liver of mammals using a fatty acid
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4851431A (en) * 1986-11-26 1989-07-25 Bar Ilan University Physiologically active and nutritional composition
EP0309086A1 (en) * 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
GB8918294D0 (en) * 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions

Also Published As

Publication number Publication date
ATE98121T1 (de) 1993-12-15
KR910005858A (ko) 1991-04-27
DE69005062D1 (de) 1994-01-20
DE69005062T2 (de) 1994-05-05
IE63449B1 (en) 1995-04-19
ZA907040B (en) 1991-06-26
FI904403A0 (fi) 1990-09-06
JPH0399013A (ja) 1991-04-24
NZ235203A (en) 1997-06-24
HK74694A (en) 1994-08-05
AU633618B2 (en) 1993-02-04
GB8920228D0 (en) 1989-10-18
IE903221A1 (en) 1991-03-13
EP0416855B1 (en) 1993-12-08
CA2024724A1 (en) 1991-03-08
AU6213590A (en) 1991-03-14
EP0416855A2 (en) 1991-03-13
EP0416855A3 (en) 1991-06-12

Similar Documents

Publication Publication Date Title
DK0416855T3 (da) Fede syrer til behandling og undgåelse af hudbeskadigelser forårsager af radioterapi
DE68909077D1 (de) Gamma-Linolensäure oder Dihomo-gamma-Linolensäure enthaltende Zubereitung zur Verbesserung der Haut.
HK37694A (en) Fatty acids compositions
DE3888273D1 (de) Medizinischer Apparat zur Behandlung mit Ultraschall.
HUT65754A (en) Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases
FI903696A0 (fi) Menetelmä antibakteeristen 5-alkyyli-6-fluori-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi
ATE163913T1 (de) Ungesättigte aliphatische dicarbonsäuren
PH23256A (en) A process for the preparation of quinolone carboxylic acid derivatives
ATE156015T1 (de) Arzneimittel zur behandlung von vulva-dystrophie oder vaginaltrockenheit
ES2045120T3 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
DE3485337D1 (de) Topische zubereitungen mit gehalt an teer und fettsaeuren.
DK0409559T3 (da) Farmaceutisk og diætetisk anvendelse af fedtsyrer
HU885915D0 (en) Process for the production of medical preparations for reducing intraocular pressure
IS1697B (is) Hliðstæð aðferð til framleiðslu á 3,3'-dithiobis (própíónsýrum) og esterum þeirra
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
GB9125602D0 (en) Method of preventing reocclusion of arteries
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
DE3681656D1 (de) Verwendung von linol- oder linolensaeure-metaboliten zur behandlung vom praemenstruellen syndrom.
ATE108331T1 (de) Verwendung von tnf zur herstellung eines arzneimittels zur behandlung von psoriasis.
FI88359C (fi) Foerfarande foer framstaellning av en kardiovaskulaer komposition att anvaendas lokalt